10 Best Canadian Biotech Stocks (May 2024)

Biotech has been one of the most promising engines of innovation in the field of healthcare and medicine.

Consequently, it’s also an avenue where a lot of big money is moving in (institutional investors, government funding, etc.).

The global biotech market size is expected to reach a trillion dollars by 2024, and it’s full of exciting investment opportunities.

Some of these best Canadian biotech stocks can be your ticket to a breakthrough investment.

Pros and Cons of Investing in Biotech in Canada

Pros
  • Powerful short-term growth potential.
  • The potential of making money in a weak market (contrarian performance).
  • Intra-industry diversification.
  • Potential to invest in breakthrough technologies.
Cons
  • No dividend stocks.
  • Inconsistent growth patterns.
  • Difficult to research.
  • No large-cap or mid-cap biotech stock in Canada

Best Canadian Biotech Stocks You Can Invest in 2024

Biotech companies are often lumped together with pharmaceutical companies, but they are not the same thing.

Even though biotech companies also develop medicine and medicinal therapies, and they have a significant overlap with pharmaceutical companies, they use living organisms (biologics) to develop healthcare products.

In contrast, pharmaceutical companies mostly work with synthetics. Vaccines, antibiotics/probiotics, antibodies, etc., all fall under the purview of biotechnology.

1. BELLUS Health

BELLUS Health Stock
  • Ticker: BLU.TO
  • Size: Small-cap
  • Forward Dividend Yield: N/A
  • Market Cap: $2.47 Billion
  • Forward P/E Ratio: -15.58

In addition to being the largest biotech company in Canada by market cap, Bellus stands out from the rest of the stocks on this list for two reasons. It’s developing a treatment for a problem that affects about 13% of the general population (Chronic cough).

That’s 48 million people in the US and Canada alone. Secondly, treatment for this problem hasn’t been approved in the US for sixty years.

BELLUS Health

The treatment is already in Phase III clinical trials stage, and since Bellus holds the patents for the biological agent behind this treatment worldwide, it may experience a powerful surge in revenue once the treatment hits the market.

Even though it may still take years, this biotech company is quite close to the end of the production pipeline.

The stock has already shown enormous return potential in the right market conditions (optimism).

It went through two growth and slump cycles between Mar 2018 and Mar 2023, going up (from its lowest point to the peak) over 900% and over 400%, respectively.

2. Fennec Pharmaceuticals

  • Ticker: FRX.TO
  • Size: Small-cap
  • Forward Dividend Yield: N/A
  • Market Cap: $350.43 Million

Fennec Pharmaceuticals caters to cancer patients, particularly children that have lost their hearing due to chemotherapy. Platinum-based chemotherapy drugs (like Cisplatin) can cause permanent hearing loss, especially in children.

These drugs are given to roughly 10% to 20% of cancer patients and cause permanent hearing loss in about 75% of the children who receive them.

Fennec Pharmaceuticals

Fennec Pharma deals with a very specific market, but it has an edge, i.e., the primary FDA-approved treatment for this product.

The FDA approved the drug in September 2022, and the stock took off after that, though the momentum was short-lived. However, the edge still exists, and it may help the stock offer good long-term returns.

3. Sernova

  • Ticker: SVA.TO
  • Size: Small-cap
  • Forward Dividend Yield: N/A
  • Market Cap: $172.90 Million
  • Forward P/E Ratio: -7.13

Sernova is a biotech company working on regenerative medicine, which aims to replace animal cells for the purpose of restoring one or more of the body’s functions.

The company already has the approval to conduct clinical studies for its highly innovative (and patented) Cell Pouch™. The Cell Pouch is an implant (made from FDA-approved materials) that will provide an organ-like environment where therapeutic cells will live and spread from.

Sernova

Combined with its other two patented technologies/research avenues, Sernova has the potential to offer alternative treatments for multiple medically managed conditions, including diabetes and Thyroid diseases.

Millions of people suffer from these diseases, and if Sernova’s cell pouch and therapeutic cells prove a viable alternative to insulin, it will be a monumental leap in healthcare.

So far, the most significant spike in the stock’s recent history lasted for a few months (between Nov 2020 and Feb 2021) and pushed the value up over 500%.

4. Arch Biopartners

  • Ticker: ARCH.V
  • Size: Micro-cap
  • Forward Dividend Yield: N/A
  • Market Cap: $87.86 Million

Arch Biopartners is a clinical-stage biotech that is developing novel therapies for a widespread problem – organ injury and inflammation. One of its treatments, i.e., LSALT Peptide (Metablok), has already gone through Phase I and II clinical trials.

It’s the company’s candidate for dealing with inflammation in the lungs, liver, and kidneys, and it was investigated for COVID-19 as well.

In the last two decades, the stock has spiked/risen multiple times. The most recent bullish phase lasted from June 2021 and December 2021 and pushed the stock up over 300%.

Positives like awards of significant grants or approval of phase III clinical trials can push the stock upward.

Similarly, negative news like research associated with trials leaving for another company may trigger a downward momentum.

5. Briacell Therapeutics

  • Ticker: BCT.TO
  • Size: Micro-cap
  • Forward Dividend Yield: N/A
  • Market Cap: $73.84 Million
  • Forward P/E Ratio: -3.42

BriaCell is developing treatments for a wide range of cancer and has eight separate treatments in the preclinical stage and one treatment that has been approved by the FDA for phase II clinical trials for advanced metastatic breast cancer patients.

Breast cancer is the most prevalent form of cancer in the world, and about 78 women are diagnosed with it just in Canada every day. Comprehensive treatment can see powerful demand in the international market.

The overall family of treatments the company is developing is even more impressive and compelling, targeting prostate and lung cancers (covering a significant segment of the total cancer patients).

The company used to be massive (in terms of market capitalization) before the great recession and is currently a fraction of its former self.

It has gone through multiple growth cycles in the last decade, and the most significant growth phase in the last five years (between May 2021 and April 2022) pushed its value up by 300%.

6. Oncolytics Biotech

Oncolytics Biotech Logo
  • Ticker: ONC.TO
  • Size: Micro-cap
  • Forward Dividend Yield: N/A
  • Market Cap: $103.49 Million
  • Forward P/E Ratio: -2.43

Oncolytics Biotech is developing a treatment that aims to trigger and augment the human body’s own response to cancer cells.

The treatment is expected to be safe and well-tolerated by humans, and the company is already midway through its clinical trials for multiple treatments. The company’s main edge is the broad-spectrum application of the biological agent it’s developing.

The stock has exhibited multiple highs and lows in the past, and if you can buy the low and hold the stock till the next high, you may have a decent chance of doubling your money.

7. Theratechnologies

  • Ticker: TH.TO
  • Size: Micro-cap
  • Forward Dividend Yield: N/A
  • Market Cap: $105.78 Million
  • Forward P/E Ratio: -5

Theratechnologies has three areas of focus – HIV, for which it has both treatments in the research pipeline and prescription products it markets; liver diseases; and cancer.

It’s still in the process of securing permission for clinical trials from the FDA for some treatments, while others (its HIV trials) are already in phase II.

One of the treatments it is developing also received a Fast-Track Designation from the FDA due to its promising prospects.

The stock has gone through two major and two minor long-term growth cycles. The last major growth phase that was spread out between Jan 2014 and May 2018 saw the stock go up over 2,700%.

8. NervGen Pharma

  • Ticker: NGEN.V
  • Size: Micro-cap
  • Forward Dividend Yield: N/A
  • Market Cap: $174.95 Million
  • Forward P/E Ratio: -9.8

As a clinical-stage biotech company, NervGen focuses on problems/illnesses associated with the nervous system, primarily spinal cord injuries, Alzheimer’s, and Multiple Sclerosis (MS).

About a million people in the US are living with MS, and roughly 6.5 million with Alzheimer’s.

Its leading drug candidate, NVG-291, which is the first of its kind for these issues (injection under the skin), is already going through Phase-1 clinical trials.

NervGen Pharma logo

The stock is relatively new and started trading on the junior exchange in 2019. It has surged up over 100% three times in the two years between Nov 2019 and Nov 2020.

9. Ceapro

  • Ticker: CZO.V
  • Size: Micro-cap
  • Forward Dividend Yield: N/A
  • Upcoming Dividend Date: May 28, 2024
  • Market Cap: $12.53 Million
  • Forward P/E Ratio: 4

Ceapro is different from all the other best Canadian biotech stocks on this list because of its diversified focus, which includes applications (for the biological agents it’s developing) other than healthcare.

The two main areas of focus are cosmeceuticals (cosmetic products with medicinal properties) and Nutraceuticals (food-derived products with additional health benefits).

It also has a patented Pressurized Gas Expanded (PGX) technology which allows companies to overcome the challenge of dying biopolymers.

The focus of the company may be unique compared to other biotech firms in Canada, but the stock’s performance has followed a similar pattern.

10. IntelGenx Technologies

  • Ticker: IGX.TO
  • Forward Dividend Yield: N/A
  • Upcoming Dividend Date: May 28, 2024
  • Market Cap: $35.26 Million

IntelGenx is a biotech company that focuses on drug delivery technologies. This includes Oral Films that make it easy to take drugs without water, Transmucosal Films that improve the absorption of a drug, Oral Topical Films, and Transdermal Patches.

The primary strength of the company is the size of the B2B market it can cater to. The delivery system can be applied to a wide array of drugs, so the company can potentially partner up with almost all pharmaceutical companies to improve their drug delivery with its technologies.

 In the last ten years, the stock has spiked at least once every year. So if you buy low and wait, you may have a strong chance of catching a spike upward and accumulating decent capital appreciation.

You may also consider looking into the following honourable mentions:

  • Medicenna Therapeutics
  • Covalon Technologies
  • Promis Neurosciences
  • Devonian Health Group
  • Microbix Biosystems
  • IBEX Technologies

What Do You Need To Know Before Investing In Biotech Companies?

When you are choosing a biotech company based on its products and research avenue rather than its financials or past performance, there are a few factors you should consider looking into.

Scope

How big/commonplace is the problem the biotech company is planning on solving?

If the company is working on a revolutionary product that aims to solve a problem millions of people around the world suffer from, its breakthrough might be quite significant.

Whether it develops and sells the product directly or simply holds the patents, a larger target audience equals a larger financial opportunity, and the company may attract a lot of investment, pushing its value up.

Biotech companies focused on rare conditions may not hold the same appeal for institutional investors unless they have no competition and stand to dominate a specific market segment for years.

Progress

How far along a biotech company is in its research or clinical trials can also give insights about the right time to buy the company.

It may be difficult to decipher and challenging to track, but if you can buy a company just before a major milestone like moving to human trials or regulatory approval (HPFB, FDA, etc.), it can help you capture a strong upward trend.

Growth Pattern

Almost all of the best Canadian biotech stocks have inconsistent growth patterns. They can spike up when the conditions are favourable but can slump down just as quickly and hard enough to neutralize any gains achieved from the spike. So they may not be ideal long-term holdings.

Analysis

The fundamental financial analysis approach may not be the best to evaluate the profitability potential of biotech stocks. Instead, you may consider analyzing them from the perspective of its technology pipeline.

One good way to check its spikes/growth spurts against milestones it has achieved, like getting approved for clinical trials or moving from Phase I to II or from II to III. If they coincide, you may consider keeping an eye on the timeline for the next milestone.

How To Buy The Best Canadian Biotech Stocks

The cheapest way to buy stocks is from discount brokers. My top choices in Canada are:

Qtrade
Readers Choice
  • 105 commission-free ETFs to buy and sell
  • Excellent customer service
  • Top-notch market research tools
  • Easy-to-use and stable platform 
Wealthsimple Trade
Low Fees
  • Stock and ETF buys and sells have $0 trading fees
  • Desktop and mobile trading
  • Reputable fintech company
  • Fractional shares available
Questrade
Well-Rounded
  • ETF buys have $0 trading fees
  • Excellent market research tools
  • Most types of registered accounts available

To learn more, check out my full breakdown of the best trading platforms in Canada here.

Conclusion

Biotech stocks in Canada might require a more active investment style to capitalize on their potential fully, so if you are looking for buy-and-forget investments, this may not be your cup of tea.

But if you are looking for short-term gains (from a few months to a couple of years) and are adequately risk-tolerant, then you may consider buying heavily discounted biotech stocks and holding them till they go up.

If you are looking for other options, these diversified healthcare stocks are worth looking into.

Photo of author
Author Bio - Christopher Liew is a CFA Charterholder with 11 years of finance experience and the creator of Wealthawesome.com. Read about how he quit his 6-figure salary career to travel the world here.

Check Out These Posts:

Leave a Comment